header logo image


Page 277«..1020..276277278279..290300..»

A century and counting: Ardmore woman turned 100 on Friday – Daily Ardmoreite

December 24th, 2020 6:57 am

Drew Butler| dbutler@gannett.com

In the evening hours of Saturday, December 18, 1920 a little girl was born in Garvin County. On Friday, December 18, 2020 that little girl, Velma Peery, celebrated her 100th birthday at Canoe Brook Ardmore Assisted Living.

Ive still got a lot of life in me, she said. I can do pretty good, but the more I sit around the stiffer I get.

Her son, Lynn Peery shared a few details about his mothers life. She lived in Garvin County for most of her life until moving into an assisted living facility in Ardmore a little over a decade ago. She was married to her husband for 57 years until his death in 1994, and the couple had four sons and one daughter.

Lynn, at the age of 74, is the baby of the family, and he said four of the five siblings are still living. One of his brothers passed away last year after an infection he developed after a surgery.

He credits his mother's and siblings' longevity with honest living and hard work along with the help of genetics.

My grandparents on her side both passed away in their early 80s, Peery said. On my dads side most of them died in their early 50s. My dad had heart surgery at 54 and we were able to keep him for another 20 years until he passed away at the age of 74.

He shared a story about his mother from the day after his father passed.

When my dad passed away, we went up and spent the night, Peery said. The next morning I got up and made coffee for everybody and took her some. She told me that she didnt like that stuff. I said what do you mean you dont like it? You and dad sat and drank coffee every morning for 57 years! She said well, he liked to talk and drink coffee in the morning, and I never liked it but I did it for him. Talk about dedication!

Peery lives in Ardmore as do several of her grandchildren. He said he visits her through the window almost every day and the entire family is looking forward to when they are able to come inside to visit and take her out for day trips.

She said she feels like a tiger in a cage because she cant get out and everybody is stuck inside, he said. We hope to get to where we can get her out to move around a bit. Were also looking forward to getting in and helping her redo her room once all of this is done.

Go here to read the rest:
A century and counting: Ardmore woman turned 100 on Friday - Daily Ardmoreite

Read More...

The Adrenomyeloneuropathy Treatment Market to grow on an emphatic note from 2019 to 2029 – PharmiWeb.com

December 24th, 2020 6:57 am

Adrenomyeloneuropathy is a rare genetic neuro-degenerative disease. Adrenomyeloneuropathy is the adult onset of adrenoleukodystrophy caused by the mutation in ABCD1 gene occurs usually in young boys. Adrenomyeloneuropathy disease affect the nerve cells in the spine and brain and the adrenal glands. Adrenomyeloneuropathy symptoms includes stiffness, weakness and pain in the legs. Adrenomyeloneuropathy is also known as progressive spastic paraparesis. Damage to the nerves of the legs which causes unsteadiness and fall, also the bladder, bowel and sexual organs are affected by the adrenomyeloneuropathy. Rare diseases affect vast numbers of people, with current data representing 30 million sufferers in the EU alone and 30 million affected in the US. There is no cure to Adrenomyeloneuropathy. However some treatment might stop the progression of Adrenomyeloneuropathy such as stem cell transplants. Blood testing, MRI test, vision screening and Skin biopsy and fibroblast cell culture are done for the diagnosis for the adrenomyeloneuropathy. Continued advances in the treatment of adrenomyeloneuropathy will further propel the adrenomyeloneuropathy treatment market.

Growing cases of rare disease and development of new and advanced treatment for rare disease is expected to boost the adrenomyeloneuropathy treatment market. Growing preference for healthy lifestyle and favorable government regulation spur the Adrenomyeloneuropathy treatment market in the forecast period. Development of new technology and devices for the diagnosis of genetic disorders will propel the adrenomyeloneuropathy treatment market. Rising focus on the research and development of new therapeutic and drug treatment and growing government funding for the orphan drug is expected to drive the adrenomyeloneuropathy treatment market.

To remain ahead of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/28645

However, stringent regulations for the drug development and high cost of associated with the treatment is expected to hinder the adrenomyeloneuropathy treatment market.

The global adrenomyeloneuropathy treatment market is segmented on basis of disease type, drug type and end user and geography.

Development of novel drugs and undergoing clinical trial for the rare disease is expected to boost adrenomyeloneuropathy treatment market. More than 3,000 drugs are in active development for one of the rare disease. Progress in genomics and biomedical science for the development of rare disease drug is expected to spur the adrenomyeloneuropathy treatment market. Various pharmaceutical companies are focusing on developing drug for the low prevalence disease types and rising funding and collaboration among the key players and government is expected to spur the adrenomyeloneuropathy treatment market.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/28645

The North America market for adrenomyeloneuropathy treatment is expected to retain its dominance, owing to increasing patient pool for rare disease, increasing government funding to accelerate the research and development for rare disease. According to Genetic and Rare Diseases Information Center, more than 25 million Americans are suffering from rare disease in United States.Europe is expected to account for the second largest share in the global adrenomyeloneuropathy treatment market owing to growing clinical trial funding programs for orphan drug development and high prevalence of adrenomyeloneuropathy and high treatment seeking rate. Asia Pacific is expected to show significant growth, owing to increasing diagnosis rate and improvement in healthcare infrastructure. China is expected to show significant growth in the adrenomyeloneuropathy treatment market, due to rising population improving R&D capability, increasing per capita heath spending. Latin America and Middle East & Africa is expected to show growth owing to lack of diagnosis and inadequate healthcare facilities and lack of skilled physicians for Adrenomyeloneuropathy Treatment market.

Examples of some of the key manufacturer present in the global adrenomyeloneuropathy treatment market are Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics among others.

You Can Request for TOC Here @

https://www.persistencemarketresearch.com/toc/28645

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsitehttps://www.persistencemarketresearch.com

Source MARKITWIRED

Continued here:
The Adrenomyeloneuropathy Treatment Market to grow on an emphatic note from 2019 to 2029 - PharmiWeb.com

Read More...

Getting to the root of why hair goes gray – messenger-inquirer

December 24th, 2020 6:57 am

Marco Kaltofen was 11 when he noticed his first white hairs. As his hair grew whiter, his middle-school friends started calling him the professor. By his mid-30s, it was completely white, as it had been for three of his grandparents. His parents went white in their 40s, so I had no chance of avoiding this, Kaltofen says.

Now 61, he is a civil engineer who lives in Boston. He wears his white hair in a ponytail. White hair is part of my identity, and I am completely at peace with it, he says.

Then there is Joe Rees, 75, a retired customs attache who lives in Washington. He is balding, but the hair that remains on the sides and in the back is the same dark brown it always has been. He jokingly attributes this to clean living and a pure heart, although, like Kaltofen, it probably is genetic. His mothers black hair didnt start to go gray until she was in her 70s, and was 50/50 when she died at 88, he says.

Still, Id rather be gray than bald, he says. That way, I wouldnt have to worry about wearing a hat all the time.

To be sure, Rees and Kaltofen are exceptions, since most people start graying in their 50s and 60s. Nevertheless, their experiences are among the many mysteries of gray, white or silver-looking hair that scientists are exploring to learn more about aging. They want to know why some people turn gray early and others late or not at all and what this might signal about their health. They also want to understand the factors that hasten graying, and even whether gray hair is reversible which could be a boon to those allergic to hair dye, or who hate spending money to keep the gray away.

Most important, studying gray hair could point to new approaches in promoting healthier aging, says Candace Kerr, health scientist administrator in the National Institute on Agings Division of Aging Biology.

While graying is one of the markers of aging aging is the ultimate risk factor for why hair goes gray it highlights the need for better understanding of the mechanisms that drive aging and age-related diseases, she says. To be able to target these pathways will be critically important for our aging population to live longer and happier lives.

Hair that looks gray, white or silver actually is colorless. Hair color comes from melanin, a pigment produced by cells in the hair follicles. Over time, these cells suffer damage and become depleted, losing their ability to make melanin. This results in new hair without pigment meaning, no color.

People use gray, white and silver interchangeably to describe hair that is turning or has turned. Its appearance whether it looks, gray, white or silver depends on how much natural color, or pigment, remains, experts say. Hair that has lost all its color typically appears white.

Studies have identified a number of factors that also may speed up gray hair, including smoking, diet, stress and genetics.

Our hair color depends on a set of specialized stem cells called melanocyte stem cells, and every time a new hair grows, these melanocyte stem cells have to divide in two and make a new melanocyte, [or] pigment cells, explains Melissa Harris, assistant professor of biology at the University of Alabama at Birmingham. These pigment cells stay in the base of your hair and their job is to produce pigment. These melanocytes reach out skinny arms, called dendritic processes, that shuttle the pigment to the hair shaft as it grows. So if all your melanocyte stem cells disappear, so do your melanocytes and so does your hair pigment. Thus gray hair.

Because stem cells directly influence hair color, studying gray hair can provide insights about why stem cells age and ultimately fail, offering important clues about the workings of other stem cells in the body for example, those found in muscles, bones and organs. In turn, these ultimately could point to whether gray hair could be a marker for disease, or the opposite, a longer life. Previous studies have not shown a relationship between life span and gray hair, including whether late onset of gray hair predicts longevity. Some research, however, indicates that gray or white hair can be a sign of early heart disease, regardless of age.

In some people, gray hair could potentially serve as indication of their health for instance when caused by stress, or a signal for those who may be developing cardiovascular disease, Kerr says. We still need to learn more about whether and, if so, how late onset of gray hair can signal better health and longevity in some people under certain circumstances, as well as whether early graying means stem cells might be aging.

There are many different stem cells in our body which may or may not age by different means, she says. How stem cells mark aging overall and how they could interact to promote aging is an important question.

This is why scientists who study gray hair regard it as a valuable research tool.

As gray hair researchers, we often have to defend why we study a cosmetic characteristic, rather than a life-threatening disease, Harris says. But what is very cool about gray hair from a scientific point of view is that we can see it with our own eyes, meaning we dont have to take invasive biopsies, and it doesnt kill you. We have asked a lot of important and interesting questions about stem cells by studying gray hair in mice. And, we are constantly on the lookout for gray-haired mice so we can use our scientific skills to find out what makes them gray.

A 2018 mouse study by Team Hair-Us (Harris nickname for her lab colleagues) found a connection between MITF (microphthalmia), a transcription factor (a protein involved in gene expression) important in managing pigment production, and the innate immune system, suggesting that some peoples hair may turn gray in response to serious illness or chronic stress. They discovered a relationship between genes involved in hair color and those that trigger an immune response to a viral infection, suggesting this interaction could increase the chances of developing gray hair.

MITF, in a sense, shields melanocyte stem cells from our own immune system, she says. Normally our immune system protects our bodies from infection. But for melanocyte stem cells, too much immune response is bad for their health, and this leads to their loss and to gray hair. Why melanocyte stem cells are so sensitive to our own natural means for protection, we still dont know.

Im very curious to see whether we see an uptick in individuals with gray hair due to coronavirus infection, she says. Unfortunately, we probably wont know because gray hair is rarely documented clinically, unless it is very extreme.

Scientists still dont know why some people turn gray early, late, or not at all, although they suspect genes, nutrients and possibly the immune system play a role in depleting melanocyte stem cells.

There is still much to learn about what regulates these stem cells and what may contribute to their loss, says Ya-Chieh Hsu, associate professor of stem cell and regenerative biology at Harvard University and principal faculty member of the Harvard Stem Cell Institute.

Among other things, Hsu studies the effect of stress on graying. Most of us are familiar with those before-and-after photographs of U.S. presidents most recently Barack Obama showing a striking increase in gray hair during their terms, even in relatively young presidents. Its known as the Marie Antoinette Syndrome, after the 18th-century French queen whose hair allegedly turned white overnight before she went to the guillotine and her death at age 38 during the French Revolution.

With the aging process, we gradually lose melanocyte stem cells one-by-one over a very long period of time, Hsu says. What we found in our research was that the stress can accelerate that process.

Hsu and her colleagues found that stress stimulates the same nerves that trigger the fight-or-flight response, which in turn causes permanent damage to the pigment-producing cells in hair follicles. The fight or flight response is thought to be a good thing in stressful situations because it can drive us and other organisms to respond to danger rapidly, Hsu says. This activation causes a spike in the neurotransmitter norepinephrine. Norepinephrine raises our heartbeat and allows us to react quickly to danger without having to think about it.

But norepinephrine also tells melanocyte stem cells to pump up their activity and proliferate, and too much norepinephrine, in this case triggered by stress, causes the melanocyte stem cells to burst into so much activity it leads to rapid depletion of the stem cell reservoir, she says. If all the stem cells are depleted, no more pigment-producing cells can be produced anymore, and the hair turns gray.

Other stress hormones, ACTH (adrenocorticotropic hormone) for example, can cause melanocyte stem cells to migrate away from the hair follicle before they can produce the melanocytes needed for hair and skin color, according to research. Such hormones are known to increase in the body after stress, and may have the potential to promote the loss of these cells, regardless of age, says study author Mayumi Ito, associate professor in the departments of cell biology and dermatology at the New York University Grossman School of Medicine.

Hsu believes the connection between stress and hair color could reveal additional information about how stress affects other biological processes. How stress affects our tissues is still poorly understood, and one of the powerful aspects about the melanocyte is that it provides a visible and highly trackable system to study stress, she says.

Ito also found that certain cell signaling proteins called endothelins (substances known to constrict blood vessels and raise blood pressure) bind to melanocyte stem cells and, in doing so, keep them healthy. Interrupting the process causes cell loss and early graying in mice. They are studying whether the same happens in human hair follicles, hoping to find ways to preserve or regenerate the key stem cells that give hair its color.

All of this raises the intriguing possibility that scientists could discover ways to prevent or reverse gray hair.

Team Hair-Us recently published a paper describing a topical drug combination that increased melanocyte stem cells in gray mice, ridding them of their gray and restoring their original fur color perhaps for good. Because the treatment originally developed to regrow hair replenished pigment-producing stem cells, the effects could be long-lasting, Harris says.

We didnt keep the mice forever so we dont know, says Harris, who plans more studies. This has made us very interested in whether gray hair really is permanent, and if we can do something about it. We really want to know and so does everyone else we talk to is whether and when we can bring this to humans.

See the original post:
Getting to the root of why hair goes gray - messenger-inquirer

Read More...

5 Ways to Maintain Good Vision and Healthy Eyes – Health Essentials from Cleveland Clinic

December 24th, 2020 6:55 am

Your eyes play a crucial role in how you move through the world and enjoy your life, from the moment you wake up to the moment you go to sleep.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services.Policy

They do the important job of capturing light. Then, different parts of the eye system (or ocular system) work together, connecting with neurons that translate and deliver messages to the brain as visual images.

For this reason, its important to keep your eyes healthy. Follow these simple measures to maintain good vision and enjoy lifelong eye health.

Eye specialists are trained to determine and improve your vision with eyeglasses, contact lenses and eye exercises. They can provide total eye care, from examinations and vision correction to the diagnosis and treatment of eye disease, says ophthalmologist Michael Millstein, MD.

You should visit your optometrist or ophthalmologist for an eye exam once every year, or if you experience eye infections or symptoms of disease such:

Eye disease is the No. 1 cause of blindness. Most diseases that cause blindness, likeglaucomaanddiabetes, can be treated or slowed down if theyre diagnosed and managed properly, Dr. Millstein says.

While theres no cure for some eye disorders, there have been major medical advances for age-relatedmacular degeneration andcataracts. By getting regular exams and discussing your family history, you and your doctor will be better able to anticipate, prevent and treat eye disease.

Not wearing your prescribed eyeglasses or contacts wont cause disease, but it can create discomfort from eyestrain,headaches or possibly even injury brought on by the lack of safe vision.

If you find wearing prescriptive lenses to be uncomfortable, ask your doctor about alternatives, like switching from eyeglasses to contact lenses or exploring corrective surgery.

Ultraviolet (UV) radiation comes from sunlight, tanning beds, black-light lamps and some other forms of light. If youre frequently exposed to UV rays, this can lead to an increased risk of cataracts or yellow raised spots on the surface of the white of the eye, such as pingueculas and pterygiums. Eye diseases such as macular degeneration, solar retinitis and corneal dystrophies have all been linked to UV exposure.

Your eyes may be more sensitive if theyre a light color, or if youre taking specific medications. You can protect your eyes while youre out in the sun by wearing prescription sunglasses, clip-on sunglasses or UV-blocking contact lenses.

Wearing safety glasses and protective goggles when you play sports or work with hazardous materials lowers your risk for eye injury, vision damage and complete loss of sight.

Being actively involved in your eye health and working with your optometrist and ophthalmologist increases your chances for maintaining good eye health and eyesight throughout your life, Dr. Millstein says.

See the original post:
5 Ways to Maintain Good Vision and Healthy Eyes - Health Essentials from Cleveland Clinic

Read More...

COVID-19 may trigger endophthalmitis, a rare eye infection that causes vision loss – TheHealthSite

December 24th, 2020 6:55 am

The COVID-19 virus has the chilling ability to invade different body organs and cause serious damage that can last for years. It can damage your body organs, affect your skin and even cause neurological problems. The damage it causes to your lungs can be permanent. This virus can also affect your eyes and give you conjunctivitis and sore eyes. Now, it has come to light that the novel coronavirus may trigger inflammation of the eyes that can lead to vision loss. Three COVID-19 patients in the US developed keratitis, an inflammation of the cornea. This is serious because this condition can lead to a sight-threatening infection of the tissues or fluids inside the eyeball called endophthalmitis. Also Read - COVID-19 vaccine: Aurobindo Pharma Inks Pact With Covaxx to develop a vaccine for India

According to a new study at the Zucker School of Medicine at Hofstra University in Hempstead, New York, this is a rare development, but it can happen. Having three cases of endophthalmitis in such a short time is exceedingly rare, and because they were all tied to COVID-19 infection it needed to be investigated, say researchers. They added that the whole point is to alert people of the association, though they cannot say specifically that COVID causes it. However, it cannot be ruled out. Also Read - Can COVID-19 vaccines bring the pandemic under control?

Of the three patients, one died from COVID-19, another had to have an eye removed despite heroic efforts to save the eye, and a third lost all sight, said researchers. All the patients were in their 60s and were treated at Northwell Healths Ophthalmology Department. Also, the three patients had underlying health problems that may have made their COVID-19 worse and made them more susceptible to other associated health conditions. The only other eye condition linked to COVID-19 has been conjunctivitis, also called pink eye, which is a minor infection. Also Read - Has new strain of Covid-19 virus already entered India? This is what health ministry says

Endophthalmitis is very rare, but it can be caused by a virus. According to one of the researchers, other cases of endophthalmitis linked to COVID-19 patients have also been reported. One of them is in Boston and another in Australia. Usual symptoms of endophthalmitis includes pain, redness and discharge from the eye. You must also be alert to swelling of the eyelids and you may experience reduced vision. If you notice any of these symptoms, consult a doctor immediately. Early treatment of this associated complication can save your vision.

According to researchers, it is unusual for keratitis to progress to endophthalmitis. A 2012 study says that only 27 of around 10,000 eyes over 15 years developed endophthalmitis because keratitis. One expert thinks that because keratitis progressing to endophthalmitis is so rare, its not possible from these findings to say that the connection between these conditions is anything but coincidental. According to them, while it is possible that the keratitis was related to COVID-19, there are very few reports to suggest this is at all common. They agree that further research is needed to confirm the findings.

(With inputs from Agencies)

Published : December 22, 2020 6:36 pm

Link:
COVID-19 may trigger endophthalmitis, a rare eye infection that causes vision loss - TheHealthSite

Read More...

Vision Benefits of America Grants $500,000 to the Pennsylvania Vision Foundation – PRNewswire

December 24th, 2020 6:55 am

PITTSBURGH, Dec. 23, 2020 /PRNewswire/ --Vision Benefits of America, Inc. (VBA), a commercial group benefits organization, today announced donations totaling $500,000 to the Pennsylvania Vision Foundation in 2020. The donations will support the foundation's mission to preserve human eyesight.

"VBA is committed to the Pennsylvania Vision Foundation and those in need of high-quality eye care," said Jeff Hollowood, CEO and President at VBA. "We are proud to increase our annual contribution to the foundation and support our Pittsburgh neighbors."

By partnering with many local, community-based non-profit organizations, the Foundation's primary Vision Benefit Program provided routine vision exams, prescription lenses and frames to approximately 685 uninsured Pennsylvanians this year. In 2020, the Foundation also granted a total of $52,000 to a host of non-profit agencies that partner and support programs serving its mission.

"The foundation is deeply appreciative of VBA's generous contribution," said Andrew Leitzel, O.D., Executive Director. "As a non-profit organization, these funds are critical to advancing our impact across the state. VBA truly supports our community and exemplifies neighbors helping neighbors."

VBA made charitable donations to organizations including Allegheny Cleanways, Andrew Carnegie Free Library and Music Hall, Big Brothers Big Sisters of Greater Pittsburgh, Boys and Girls Club of Carnegie, Carnegie Police Department Toys for Tots, Carnegie Salvation Army Food Pantry, Community Kitchen Pittsburgh, Jeremiah's Place, Mt. Nittany Health Foundation, Outreach Teen and Family Services, Reading Ready Pittsburgh, Sarah Heinz House Association, Storehouse for Teachers and 412 Food Rescue.

VBA has been a proud partner of the foundation since its inception in 2007.

About VBAFounded in 1965 as one of the first preferred provider organizations (PPO) in the nation, VBA has proudly offered group vision benefits to corporations, municipalities, schools, health and welfare funds, hospitals and health maintenance organizations for over 50 years. Seeking to capitalize on its experience and expand its offerings beyond vision, VBA also provides cost-effective dental solutions across the nation through plans administered and underwritten by the TruAssure Insurance Company. Some plans may not be available in all states. For information, please visit http://www.vbaplans.com.

About the Pennsylvania Vision Foundation

The Pennsylvania Vision Foundation, an affiliate of VBA, was founded in 2007 as a 501(c)(3) charitable foundation. Its mission is to provide essential eye care through vision exams, prescription lenses and frames to those in need. Its purpose is to conduct and finance projects that will help foster and preserve human eyesight through the science of optometry. It strives to help support advancement in optometry through education and technology. To date, the Foundation has proudly assisted more than 6,055 uninsured Pennsylvanians.

Media Contact

Contact: Emily ShraderTelephone: 412-881-4900 x 232Email: [emailprotected]

Related Images

vision-benefits-of-america-grants.png Vision Benefits of America Grants $500,000 to Pennsylvania Vision Foundation

SOURCE VBA

See the original post:
Vision Benefits of America Grants $500,000 to the Pennsylvania Vision Foundation - PRNewswire

Read More...

Such a Personal, Private Thing: Rethinking the Home Pregnancy Test – The New York Times

December 24th, 2020 6:55 am

When Tiffany Jesteadt, who was born blind because of a hereditary disorder, thought she might be pregnant, her husband, who is sighted, read her the results, not by choice but by necessity. It took away some of the magic, she said, explaining how shows and movies often depict wives surprising their husbands by cleverly hiding the positive pregnancy test.

Getting to tell your husband it is cultural, said Ms. Jesteadt, 33, an organization development practitioner for the U.S. Marine Corps. While she and her husband tell each other everything, she said, disclosing information about her own body is something that a woman should be able to control.

Making the test experience more private also helps reduce the judgment many blind women say they experience on their paths to motherhood.

Josselyn Sosa was a college senior when she found out she was pregnant. At first, Ms. Sosa turned to a trusted friend who accompanied her to buy a test in a CVS store that she then took in its bathroom. Her friend also had impaired vision and couldnt read the results, either. So Ms. Sosa visited the health center at her small college in Texas, where a doctor told her, I am so sorry, but it came back positive.

She felt she could provide her opinion, said Ms. Sosa, 28, who was born with congenital glaucoma in her right eye and lost sight in her left eye because of retinal detachment when she was 12. She had been dating her now-husband, who is also blind, for only a short time. I just wanted to get out to deal with it by myself, she said. It was such a big deal for me.

Ms. Sosa went on to deliver a baby girl, now 4 years old. She graduated this month with a degree in hospitality administration and shes pregnant with her second child, due in June.

For her current pregnancy, Ms. Sosa used the Be My Eyes app. It was a better experience, but she still felt she was giving up her privacy, she said.

See the original post:
Such a Personal, Private Thing: Rethinking the Home Pregnancy Test - The New York Times

Read More...

Did a cataract operation improve my memory? – The Irish Times

December 24th, 2020 6:55 am

The Irish playwright Thomas Kilroy said that when he had cataracts removed from his eyes his memory improved. He was delighted with the improvement in his eyesight and the memory boost was a welcome bonus. Bad eyesight and memory loss had been bothering him for some time. Now, life was taking on a welcome new outlook.

I was amazed at this claim. Yes, of course his eyesight improved when the cataracts were removed, but surely memory is a completely different thing altogether? Was he serious? I must admit, I was highly sceptical. It didnt seem possible to my non-medical/scientific brain that such a thing could happen. How could his memory improve? I mean, we all know playwrights have wonderful imaginations. After all, that is one of the reasons why they write plays in the first place, isnt it?

The reason I was so interested in this subject was because I was going for a cataract operation the following week and, as it so happened, my memory was beginning to slip (why wouldnt it at 80 years?). So, if this guy is right, I could be killing two birds with the one stone. Bingo, new eyes and my once great memory back on track. I might be able to get my job back in the newsroom, although I might appear a bit of a dinosaur to the present bright young incumbents.

By the way, for those of you who do not know what cataracts are, they are a clouding of the lens in the eye which leads to a decrease in vision. Cataracts cause half of all cases of blindness and 33 per cent of visual impairment worldwide. They are most commonly due to aging.

They kind of sneaked up on me. Never realised what was happening. I knew my driving was going to hell and my judgment was not as good as it used to be. My reversing into parking spaces was poor. Driving was particularly dodgy at night and headlights from other cars would blind me. I could only drive slowly, which usually resulted in younger, impatient drivers tailgating me and trying to run me off the road. I nearly gave up driving at night, except to drop down to the village for an evening meal with my wife.

Being a slow learner, I didnt realise what was going on. I put it down to old age. I have convinced myself that everything that goes wrong nowadays is due to old age. The cracks are starting to appear, big time. Here was the big clue in front of me hopeless, dangerous night driving and I could not see the reason for it. (Ill never get into the Garda Sochnas detective unit, thats for sure.)

The clues were everywhere. But, like Mr Magoo, I could not see them. Take my golf for instance. I mean I was never in the Rory McIlroy league or ever likely to be, but I could always finish 18 holes without having a heart attack or losing too many balls into the water or the gorse bushes. But suddenly I began misjudging shots, hitting fresh-air shots, handicap going out, losing bets on rounds with friends. Yes, the roof was falling in. And still the penny never dropped. Never copped on that all this was very strange. No, it was simply old age stalking me again: the usual mantra.

Then, suddenly, the sorry saga came to an end and the reason for my discomfort and frustration was explained to me.

I had gone to my optician to get a new pair of reading glasses. She did an eye test and announced I had bad cataracts in one eye and they were starting to develop in the second. They would have to be removed immediately.

Wow, a mixture of relief and concern followed this diagnosis. Glad that I knew what had been happening to me, but a little concerned about what would happen in the operation (would it go wrong and would I bleed to death?)

I need not have worried. It was the easiest and most painless hospital procedure I ever had. It only took about half an hour. It is a simple operation with an almost 100 per cent success rate. I had spent more time answering questions and filling in forms in triplicate then having the actual job done.

After the operation I was wheeled back to my ward and got a lovely cup of tea and one of the nicest scones I ever tasted. Id nearly go back again to get one of those scones.

I can now proudly declare that my eyesight is exceptionally good. I can practically see the grass growing. No problem with night driving. Long distance eyesight is simply brilliant. My long distance sight is so good that my golf colleagues are constantly asking me to tell them where their ball went. I am quite chuffed by this new recognition. I am pleased to be able to help. Of course I have no difficulty in finding my own ball, mainly because it doesnt go very far.

Has the operation improved my memory, as it did for Thomas Kilroy? I suppose it has to a certain extent insofar as everything has quickened up considerably and all my mental reactions seem to be better. Im generally much sharper in my mental reflexes. Sorry for doubting you, Thomas. But please dont ask me to remember names. It was a big problem before the operation and it still is, Im afraid.

That reminds me of the old memory joke about the man who visits his friend in a nursing home. To test the patient he posed the question: Do you know who I am? The friend replies: Ask the matron, shell tell you.

Read more:
Did a cataract operation improve my memory? - The Irish Times

Read More...

Is Spero Therapeutics Inc (SPRO) a Winner in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

Spero Therapeutics Inc (SPRO) is near the top in its industry group according to InvestorsObserver. SPRO gets an overall rating of 73. That means it scores higher than 73 percent of stocks. Spero Therapeutics Inc gets a 88 rank in the Biotechnology industry. Biotechnology is number 29 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Spero Therapeutics Inc (SPRO) stock has gained 17.83% while the S&P 500 is down -0.12% as of 10:24 AM on Tuesday, Dec 22. SPRO is up $3.39 from the previous closing price of $19.00 on volume of 235,658 shares. Over the past year the S&P 500 has risen 14.47% while SPRO is up 114.46%. SPRO lost -$4.21 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Spero Therapeutics Inc (SPRO) Stock.

Read the rest here:
Is Spero Therapeutics Inc (SPRO) a Winner in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Aclaris Therapeutics Inc (ACRS) the Top Pick in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

A rating of 78 puts Aclaris Therapeutics Inc (ACRS) near the top of the Biotechnology industry according to InvestorsObserver. Aclaris Therapeutics Inc's score of 78 means it scores higher than 78% of stocks in the industry. Aclaris Therapeutics Inc also received an overall rating of 63, putting it above 63% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 63 would rank higher than 63 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Aclaris Therapeutics Inc (ACRS) stock has gained 9.93% while the S&P 500 has fallen -0.12% as of 10:24 AM on Tuesday, Dec 22. ACRS has risen $0.60 from the previous closing price of $6.04 on volume of 654,019 shares. Over the past year the S&P 500 is up 14.47% while ACRS has risen 264.84%. ACRS lost -$1.35 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aclaris Therapeutics Inc (ACRS) Stock.

Continued here:
Is Aclaris Therapeutics Inc (ACRS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

The 66 rating InvestorsObserver gives to Allakos Inc (ALLK) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, ALLKs 66 overall rating means the stock scores better than 66 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Allakos Inc (ALLK) stock has risen 0.58% while the S&P 500 has fallen -0.22% as of 3:25 PM on Tuesday, Dec 22. ALLK is higher by $0.84 from the previous closing price of $144.00 on volume of 295,894 shares. Over the past year the S&P 500 is up 14.35% while ALLK is higher by 41.36%. ALLK lost -$2.74 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Allakos Inc (ALLK) Stock.

Continue reading here:
Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Frequency Therapeutics Inc (FREQ) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

Frequency Therapeutics Inc (FREQ) is near the top in its industry group according to InvestorsObserver. FREQ gets an overall rating of 74. That means it scores higher than 74 percent of stocks. Frequency Therapeutics Inc gets a 90 rank in the Biotechnology industry. Biotechnology is number 29 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 74 means the stock is more attractive than 74 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Frequency Therapeutics Inc (FREQ) stock is higher by 6.57% while the S&P 500 is lower by -0.11% as of 10:57 AM on Tuesday, Dec 22. FREQ has risen $2.08 from the previous closing price of $31.66 on volume of 140,241 shares. Over the past year the S&P 500 is higher by 14.48% while FREQ has risen 87.13%. FREQ lost -$0.69 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Frequency Therapeutics Inc (FREQ) Stock.

Read the original here:
Is Frequency Therapeutics Inc (FREQ) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Is Crispr Therapeutics AG (CRSP) the Top Pick in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

Crispr Therapeutics AG (CRSP) is around the top of the Biotechnology industry according to InvestorsObserver. CRSP received an overall rating of 65, which means that it scores higher than 65 percent of all stocks. Crispr Therapeutics AG also achieved a score of 80 in the Biotechnology industry, putting it above 80 percent of Biotechnology stocks. Biotechnology is ranked 33 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Crispr Therapeutics AG (CRSP) stock has risen 17.22% while the S&P 500 is down -0.3% as of 2:36 PM on Monday, Dec 21. CRSP has gained $25.59 from the previous closing price of $148.61 on volume of 4,067,713 shares. Over the past year the S&P 500 has risen 14.71% while CRSP has gained 156.63%. CRSP lost -$3.25 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Read more:
Is Crispr Therapeutics AG (CRSP) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Spectrum Pharmaceuticals, Inc. (SPPI) the Top Pick in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

The 45 rating InvestorsObserver gives to Spectrum Pharmaceuticals, Inc. (SPPI) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 49 percent of stocks in the Biotechnology industry, SPPIs 45 overall rating means the stock scores better than 45 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 45 would rank higher than 45 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Spectrum Pharmaceuticals, Inc. (SPPI) stock is trading at $4.27 as of 11:42 AM on Monday, Dec 21, a drop of -$0.10, or -2.29% from the previous closing price of $4.37. The stock has traded between $4.22 and $4.50 so far today. Volume today is light. So far 821,900 shares have traded compared to average volume of 1,733,705 shares.

Click Here to get the full Stock Score Report on Spectrum Pharmaceuticals, Inc. (SPPI) Stock.

Link:
Is Spectrum Pharmaceuticals, Inc. (SPPI) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index – GlobeNewswire

December 22nd, 2020 4:59 pm

WESTLAKE VILLAGE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020. The inclusion will become effective prior to the U.S. market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index. According to NASDAQ, the NBI is reconstituted annually in December in accordance with a set of eligibility criteria including minimum market capitalization and average daily trading volume. The index currently has 198 securities as its components. For more information about the NBI, please visit https://indexes.nasdaqomx.com/index/overview/nbi.

About Arcutis - Bioscience, applied to the skin.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The companys lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit http://www.arcutis.com or follow the company on LinkedIn and Twitter.

Investors and Media:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

Continued here:
Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index - GlobeNewswire

Read More...

Where Does Akero Therapeutics Inc (AKRO) Stock Fall in the Biotechnology Field? – InvestorsObserver

December 22nd, 2020 4:59 pm

The 62 rating InvestorsObserver gives to Akero Therapeutics Inc (AKRO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, AKROs 62 overall rating means the stock scores better than 62 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Akero Therapeutics Inc (AKRO) stock has gained 3.4% while the S&P 500 is lower by -0.22% as of 3:14 PM on Tuesday, Dec 22. AKRO has gained $0.87 from the previous closing price of $25.62 on volume of 255,146 shares. Over the past year the S&P 500 is higher by 14.35% while AKRO has gained 21.96%. AKRO lost -$2.16 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Akero Therapeutics Inc (AKRO) Stock.

Read the rest here:
Where Does Akero Therapeutics Inc (AKRO) Stock Fall in the Biotechnology Field? - InvestorsObserver

Read More...

Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 – Yahoo Finance

December 22nd, 2020 4:59 pm

Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19

SAN FRANCISCO and LONDON, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Institutes of Healths (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of VIR-7831 for the treatment of hospitalized adults with COVID-19. VIR-7831 (also known as GSK4182136) is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) investigational monoclonal antibody that was selected based on its potential to neutralize the virus, kill infected cells, provide a high barrier to resistance and achieve high concentrations in the lungs (one of the major sites of infection).

ACTIV-3 is one of several ongoing trials in the NIHs ACTIV program, an NIH led public-private partnership designed to accelerate development of the most promising treatments and vaccine candidates for COVID-19. ACTIV-3 has been designed as a master protocol that allows for the simultaneous evaluation of multiple investigational therapeutics as they become available, but within the same clinical trial structure, across multiple trial sites.

George Scangos, Ph.D., chief executive officer of Vir, said: Recent data suggest that the neutralizing activity of antibodies may be insufficient to protect hospitalized adults from the most severe consequences of COVID-19. We are hopeful that the differentiating factors and broad anti-coronavirus activity of VIR-7831 may allow it to help those patients and add to our preparedness for related coronaviruses that could emerge in the future.

Dr. Hal Barron, chief scientific officer and president R&D, GSK, said: With new infection and hospitalization rates reaching record highs, the world needs multiple options to help combat this pandemic. We are developing solutions to fight this virus, from prevention through treatment, to provide relief from COVID-related illness. Our treatment option, VIR-7831, which has a high barrier to resistance and has the potential to neutralize the virus and kill infected cells, could allow this treatment to be effective for patients in hospital settings, where other antibodies have so far not shown an impact.

Story continues

In addition to the Phase 3 ACTIV-3 trial, VIR-7831 is also being evaluated in the global Phase 2/3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial for the early treatment of COVID-19 in adults at high risk of hospitalization. The Phase 3 part of the COMET-ICE trial is assessing the safety and efficacy of a single intravenous (IV) infusion of VIR-7831 or placebo in approximately 1,300 non-hospitalized participants globally. The primary efficacy endpoint is the proportion of adults who have progression of COVID-19 as defined by the need for hospitalization or death within 29 days of randomization. The COMET clinical development program for VIR-7831 also includes a planned Phase 3 trial for the prevention of symptomatic infection.

ACTIV-3 Clinical Trial DesignThe ACTIV-3 trial arm evaluating VIR-7831 will initially compare 300 participants who have been hospitalized with mild to moderate COVID-19 with fewer than 13 days of symptoms, who will receive either VIR-7831 or placebo. Participants also will receive standard care for COVID-19, including the FDA-approved antiviral remdesivir. Five days after dosing, participants clinical status will be assessed, based on need for supplemental oxygen, mechanical ventilation, or other supportive care. If the VIR-7831 treatment arm appears to have a positive benefit:risk profile, the trial will enroll an additional 700 participants, including those who are more severely ill (i.e., adults with organ failure requiring mechanical support, or COVID-19-associated dysfunction of organs other than the lungs). Trial participants will be followed for 90 days following enrollment to analyze their response to treatment. The primary efficacy endpoint is the participants sustained recovery for 14 days after release from the hospital.

About VIR-7831 / GSK4182136VIR-7831 (GSK4182136) is a monoclonal antibody for which preclinical data suggest its ability to neutralize SARS-CoV-2 live virus in vitro and in vivo. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7831/GSK4182136 has been engineered with the potential to enhance lung bioavailability and have an extended half-life.

About the Vir and GSK CollaborationIn April 2020, Vir and GSK entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Virs proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSKs expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.

About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit http://www.vir.bio.

About GSK GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit http://www.gsk.com/about-us.

Vir Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, plan, potential, aim, promising and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of VIR-7831 in treating hospitalized patients with COVID-19, the potential benefits of participating in the ACTIV-3 trial, the ability of using a combination of a potent effector function and neutralization capabilities in enhancing the efficacy of monoclonal antibodies to treat hospitalized patients, the efficacy and safety of a single intravenous (IV) infusion of VIR-7831, Virs plans around the evaluation of interim analyses and the expected timing of clinical study results for VIR-7831, the ability of VIR-7831 to prevent symptomatic infection, the clinical trial design around ACTIV-3 as well as statements around the potential benefits of Vir and GSKs collaboration in addressing the current COVID-19 pandemic and future outbreaks of the disease. Many factors may cause differences between current expectations and actual results, including delays or failures in planned patient enrollment or retention, clinical site activation rates or clinical trial enrollment rates that are lower than expected, unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, challenges in accessing manufacturing capacity, successful development and/or commercialization of alternative product candidates by our competitors, changes in expected or existing competition, delays in or disruptions to our business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes.

GSK Cautionary Statement Regarding Forward-Looking StatementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSKs Principal risks and uncertainties section of the Q2 Results and any impacts of the COVID-19 pandemic.

Registered in England & Wales:No. 3888792

Registered Office:980 Great West RoadBrentford, MiddlesexTW8 9GS

Read this article:
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 - Yahoo Finance

Read More...

Is Syros Pharmaceuticals Inc (SYRS) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

The 51 rating InvestorsObserver gives to Syros Pharmaceuticals Inc (SYRS) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 60 percent of stocks in the Biotechnology industry, SYRSs 51 overall rating means the stock scores better than 51 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 51 means the stock is more attractive than 51 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Syros Pharmaceuticals Inc (SYRS) stock is higher by 9.3% while the S&P 500 has fallen -0.66% as of 1:34 PM on Friday, Dec 18. SYRS has risen $1.03 from the previous closing price of $11.07 on volume of 392,085 shares. Over the past year the S&P 500 has gained 15.37% while SYRS has risen 94.53%. SYRS lost -$1.65 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Syros Pharmaceuticals Inc (SYRS) Stock.

Read more:
Is Syros Pharmaceuticals Inc (SYRS) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors – GlobeNewswire

December 22nd, 2020 4:58 pm

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform, today announced the appointment of Mani Mohindru, PhD to the Companys board of directors. Dr. Mohindru brings to CytomX deep and varied experience across the life sciences industry, with particular experience in finance and corporate strategy.

We are pleased to welcome Mani to CytomXs board of directors, commented Sean McCarthy, D.Phil., president, chief executive officer (CEO) and chairman of CytomX. Mani brings a unique combination of scientific, financial and strategic acumen to the board that will prove invaluable as we advance our clinical pipeline towards multiple significant data updates in 2021 and execute towards our long-term vision.

Dr. Mohindru is an experienced biotech executive with several years of biopharmaceutical industry leadership as well as Wall Street experience. Most recently she was the CEO of CereXis, Inc., a biotech company focused on rare tumor indications. Earlier, she also served as chief financial officer and chief strategy officer at Cara Therapeutics (Nasdaq: CARA) and chief strategy officer at Curis, Inc. (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent many years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. She also co-founded a privately-held biotechnology company and was a healthcare industry consultant. Currently, she is a member of the board of directors of SAB Biotherapeutics, a clinical-stage biopharmaceutical company advancing a new class of immunotherapies. Dr. Mohindru received her Ph.D. in neurosciences from Northwestern University and her Masters in biotechnology and BS in human biology (Hons) from the All India Institute of Medical Sciences, New Delhi, India.

I am excited to join CytomXs board as the Company continues to develop and advance its innovative Probody platform, which holds the potential to unlock highly effective cancer therapies by exploiting previously undruggable targets, Dr. Mohindru added. I look forward to leveraging my experiences across drug development and corporate strategy to help advance the Companys leadership in the field of conditional activation of antibody-drug conjugates and other therapeutic modalities.

About CytomX TherapeuticsCytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational antibody therapeutics, based on our Probody technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.

Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment. As a result, Probody therapeutics are intended to bind selectively to tumors and decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential first-in-class therapeutic candidates against novel, difficult to drug targets and potential best-in-class immunotherapeutic candidates against clinically validated targets. The CytomX clinical-stage pipeline includes first-in-class product candidates against previously undruggable targets, including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues. The CytomX clinical-stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned anti-PD-L1 Probody therapeutic, CX-072. For additional information about CytomX Therapeutics, visit http://www.cytomx.com and follow us on LinkedIn and Twitter.

CytomX Therapeutics Forward-Looking Statements

This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety and efficacy or progress of CytomXs or any of its collaborative partners product candidates, including CX-2009, CX-2029, BMS-986249 and BMS-986288, the potential benefits or applications of CytomXs Probody platform technology, CytomXs ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of CX-2009, CX-2029, BMS-986249 and BMS-986288, and the timing of the commencement of clinical trials and other development milestones. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomXs novel Probody Platform technology; CytomXs clinical trial product candidates are in the initial stages of clinical development and its other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the business, research and clinical operations of CytomX or its partners, including the development of preclinical drug candidates due to delays in and disruption of research activities and the development of clinical drug candidates due to delays in or disruption of clinical trials, including impacts on the enrollment of patients in clinical trials or other clinical trial disruptions; the possibility that the results of early clinical trials may not be predictive of future results; the possibility that CytomXs clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; CytomXs dependence on the success of CX-2009, CX-2029, BMS-986249, BMS-986288, and CX-072; CytomXs reliance on third parties for the manufacture of the companys product candidates; and possible regulatory developments inthe United Statesand foreign countries. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomXs Quarterly Report on Form 10-Q filed with theSEConNovember 5, 2020. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

CytomX Contact:Chau Cheng, PhD MBAVP, Investor Relations & Corp. Communicationsccheng@cytomx.com650-273-4999

Investor and Media Contact:Stern Investor RelationsStephanie Ascherstephanie.ascher@sternir.com212-362-1200

See the rest here:
CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors - GlobeNewswire

Read More...

LanzaTech and TeselaGen Biotechnology Sign New Multi-Year Deal to Advance Carbon Remediation via Biological Processes – PR Web

December 22nd, 2020 4:58 pm

The ability to economically recycle poisonous greenhouse gasses like carbon oxides into valuable products via a biological process is an amazing achievement.

San Francisco and Chicago (PRWEB) December 21, 2020

Today, LanzaTech announced the signing of a new multi-year contract with TeselaGen Biotechnology, extending their relationship through 2025. The two companies have been collaborating since 2016 on the informatics behind high-throughput synthetic biology workflows. Over that time, LanzaTech has continued to experience rapid growth, showing the feasibility to synthesize more than 100 different molecules using its carbon-eating bacteria, and demonstrating the need for a significant scaleup of its R&D operations.

"Designing and optimizing biology is not easy, and we are in a race to recycle more carbon before it is too late. This collaboration with TeselaGen will extend our capabilities and help us achieve our goals", said Dr. Sean Simpson Chief Scientific Officer and Co-founder at LanzaTech. TeselaGen has developed one of the most advanced cloud-based solutions for designing, building, and optimizing complex biological workflows and products. We are enthusiastic about extending our collaboration with the TeselaGen team, added Dr. Michael Kpke, Vice President Synthetic Biology at LanzaTech.

LanzaTech has developed unique wet-lab capabilities, as well as some advanced bioinformatic solutions tailored for optimizing their anaerobic microbes. With input from LanzaTech, we have developed an operating system for biotechnology that can interoperate with existing infrastructure and services, facilitating the flow of information across various services, biotech vendors, external databases, algorithms, and automated equipment. This helps LanzaTech keep tight control of their biological design automation process, from start to finish. We want to enable the biotech industry to iterate faster, helping it reduce costs and time-to-market, said Dr. Eduardo Abeliuk, Chief Executive Officer and Co-founder of TeselaGen.

The ability to economically recycle poisonous greenhouse gas like carbon oxides into valuable products via a biological process is an amazing achievement. We are excited to continue helping this very talented team at LanzaTech push the limits of whats possible through Synthetic Biology, added Michael Fero, Chief Operating Officer and Co-founder of TeselaGen. In particular, we look forward to bringing our recently published iterative machine learning approach to the task of making LanzaTechs microbes even more efficient, he added.

About LanzaTechCarbon recycling company, LanzaTech is a global leader in gas fermentation, making sustainable fuels and chemicals via biological conversion of waste carbon emissions, including industrial off-gases; syngas generated from any biomass resource (e.g., municipal solid waste), organic industrial waste, agricultural waste); and reformed biogas. LanzaTechs expertise in fermentation scale-up, reactor design, machine learning, and synthetic biology has enabled the company to commercialize its recycling process and demonstrate the production of over 100 different chemicals. With global investors and partners, LanzaTech has a pipeline of commercial projects around the world and is working across the supply chain to provide novel circular solutions to mitigate carbon by producing consumer goods that would otherwise come from fresh fossil resources. Founded in New Zealand, LanzaTech is based in Illinois, USA, and employs more than 170 people, with locations in China, India, and Europe. Further information is available at http://www.LanzaTech.com

About TeselaGenTeselaGen is building an artificial intelligence-enabled operating system for biotechnology. TeselaGen's cloud-based solution bridges the gaps between biologists who are designing valuable products - like vaccines, biologic medicines, and sustainably sourced chemicals - lab technicians who are running and optimizing experimental workflows, and bioinformaticians who analyze experimental data and have to recommend new experiments. TeselaGen is privately held and is based in San Francisco, CA. The company has received early recognition in the form of various US National Science Foundation funding awards, a CORFO award, and a Bio-IT World Best Practices Award. TeselaGen uses its proprietary Synthetic Evolution technology to help companies efficiently design and optimize biological products. Follow @teselagen on Twitter and learn more at http://www.teselagen.com

Share article on social media or email:

See original here:
LanzaTech and TeselaGen Biotechnology Sign New Multi-Year Deal to Advance Carbon Remediation via Biological Processes - PR Web

Read More...

Page 277«..1020..276277278279..290300..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick